Chelsea S Pan1, Julian J Weiss1,2, Lindsay T Fourman1, Colleen Buckless3, Karen L Branch4, Hang Lee5, Martin Torriani3, Madhusmita Misra6,7, Takara L Stanley1,6. 1. Metabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 2. Yale School of Medicine, New Haven, CT, USA. 3. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 4. Translational and Clinical Research Center, Massachusetts General Hospital, Boston, MA, USA. 5. Biostatistics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 6. Pediatric Endocrine Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 7. Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in young adults with obesity. Obesity is associated with relative growth hormone (GH) deficiency, and data from animal studies and from humans with pituitary GH deficiency suggest a role for GH deficiency in the pathogenesis of NAFLD. The effects of GH on NAFLD in those with obesity are unknown, however, prompting this pilot study to assess effects of GH administration on measures of NAFLD in young adults. METHODS: Twenty-four men and women aged 18-29 years with BMI ≥ 30 kg/m2 , hepatic fat fraction (HFF) ≥ 5% on proton magnetic resonance spectroscopy (1 H-MRS) and insulin-like growth factor 1 (IGF-1) z-score ≤ 0 were randomized to treatment with recombinant human GH (rhGH) versus no treatment for 24 weeks. The primary endpoint was change in HFF. RESULTS: Compared to no treatment, the effect size of rhGH on absolute HFF over 24 weeks was -3.3% (95% confidence interval: -7.8%, 1.2%; p = .14). At 24 weeks, HFF < 5% was achieved in 5 of 9 individuals receiving rhGH versus 1 of 9 individuals receiving no treatment (p = .04). rhGH did not significantly reduce ALT, AST or GGT. Serum IGF-1 increased as expected with rhGH treatment, and there were no changes in fasting lipids, C-reactive protein, fasting glucose or 2-h glucose following an oral glucose tolerance test. CONCLUSION: Data from this pilot study suggest that rhGH treatment in young adults with obesity and NAFLD may have benefits to reduce liver fat content, although larger studies are needed to confirm this effect.
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in young adults with obesity. Obesity is associated with relative growth hormone (GH) deficiency, and data from animal studies and from humans with pituitary GH deficiency suggest a role for GH deficiency in the pathogenesis of NAFLD. The effects of GH on NAFLD in those with obesity are unknown, however, prompting this pilot study to assess effects of GH administration on measures of NAFLD in young adults. METHODS: Twenty-four men and women aged 18-29 years with BMI ≥ 30 kg/m2 , hepatic fat fraction (HFF) ≥ 5% on proton magnetic resonance spectroscopy (1 H-MRS) and insulin-like growth factor 1 (IGF-1) z-score ≤ 0 were randomized to treatment with recombinant human GH (rhGH) versus no treatment for 24 weeks. The primary endpoint was change in HFF. RESULTS: Compared to no treatment, the effect size of rhGH on absolute HFF over 24 weeks was -3.3% (95% confidence interval: -7.8%, 1.2%; p = .14). At 24 weeks, HFF < 5% was achieved in 5 of 9 individuals receiving rhGH versus 1 of 9 individuals receiving no treatment (p = .04). rhGH did not significantly reduce ALT, AST or GGT. Serum IGF-1 increased as expected with rhGH treatment, and there were no changes in fasting lipids, C-reactive protein, fasting glucose or 2-h glucose following an oral glucose tolerance test. CONCLUSION: Data from this pilot study suggest that rhGH treatment in young adults with obesity and NAFLD may have benefits to reduce liver fat content, although larger studies are needed to confirm this effect.
Authors: A Dutour; I Abdesselam; P Ancel; F Kober; G Mrad; P Darmon; O Ronsin; V Pradel; N Lesavre; J C Martin; A Jacquier; Y Lefur; M Bernard; B Gaborit Journal: Diabetes Obes Metab Date: 2016-05-31 Impact factor: 6.577
Authors: Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos Journal: J Pediatr Gastroenterol Nutr Date: 2017-02 Impact factor: 2.839
Authors: Stephen A Harrison; Mustafa R Bashir; Cynthia D Guy; Rong Zhou; Cynthia A Moylan; Juan P Frias; Naim Alkhouri; Meena B Bansal; Seth Baum; Brent A Neuschwander-Tetri; Rebecca Taub; Sam E Moussa Journal: Lancet Date: 2019-11-11 Impact factor: 79.321
Authors: G Johannsson; P Mårin; L Lönn; M Ottosson; K Stenlöf; P Björntorp; L Sjöström; B A Bengtsson Journal: J Clin Endocrinol Metab Date: 1997-03 Impact factor: 5.958
Authors: G Aimaretti; C Baffoni; L DiVito; S Bellone; S Grottoli; M Maccario; E Arvat; F Camanni; E Ghigo Journal: Eur J Endocrinol Date: 2000-04 Impact factor: 6.664
Authors: Dimitrios A Koutoukidis; Nerys M Astbury; Kate E Tudor; Elizabeth Morris; John A Henry; Michaela Noreik; Susan A Jebb; Paul Aveyard Journal: JAMA Intern Med Date: 2019-09-01 Impact factor: 21.873